cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.60645/bdc-471s-0975
title: Multi-Ethnic Study of Atherosclerosis (BioLINCC)

description: 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. 

Data available for request include phenotypic data previously released on BioLINCC as well as raw images (E.g. Echocardiogram) and raw tracing data files (e.g. Electrocardiogram). These new data are intended to be made available to interested researchers via BioData Catalyst, will include participants irrespective of participation in genetics (i.e. the full MESA cohort), and may be merged with currently posted (to dbGaP) phenotype and molecular datasets (WGS, GWA, RNA Seq, Methylation, Metabolomics, and Proteomics).
DOI: 10.5281/zenodo.18505200
title: Annotated images when searching for intruders on top of the train for Use Case 15

description: Annotated images when searching for intruders on top of the train for Use Case 15
DOI: 10.60645/bdc-r2hx-5fvm
title: Heart Failure Network - Effectiveness of Ultrafiltration in Treating People with Acute Decompensated Heart Failure and Cardiorenal Syndrome (HFN CARRESS - BioLINCC)

description: 
<u>Objective</u><br>The [CARRESS trial](http://clinicaltrials.gov/study/NCT00608491) examined the effectiveness of ultrafiltration compared with a strategy of diuretic-based stepped pharmacologic therapy on renal function and weight loss in patients with heart failure who have worsening renal function and persistent congestion.<br>

<u>Background</u><br>Acute cardiorenal syndrome is defined as worsening renal function in patients with acute decompensated heart failure. It occurs in 25 to 33% of patients and is associated with poor outcomes. Current heart failure treatments focus on removing excess fluid buildup, however administration of intravenous diuretics may contribute to worsening renal function. Venovenous ultrafiltration is one alternative therapy that may be effective in patients with acute decompensated heart failure complicated by acute cardiorenal syndrome and persistent congestion<br>

<u>Subjects</u><br>A total of 188 patients were randomized.<br>

<u>Design</u><br>Hospitalized subjects were randomly assigned to receive either ultrafiltration therapy or pharmacologic therapy. Ultrafiltration was performed at a fluid-removal rate of 200 ml per hour and loop diuretics were discontinued for the duration of the intervention. The addition of intravenous vasodilators or positive inotropic agents was prohibited, unless they were deemed to be necessary as rescue therapy. Patients assigned to stepped pharmacologic therapy received intravenous diuretics to manage congestion and maintain a urine output of 3 to 5 liters per day. In both groups, the assigned treatment strategy was to be continued until the signs and symptoms of congestion in the patient were reduced as much as possible. The primary end points were baseline changes in serum creatinine and weight as assessed at 96 hours after treatment assignment.<br>

<u>Conclusions</u><br>The use of a stepped pharmacologic-therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function, and there was a similar amount of weight loss between the two groups. Ultrafiltration was associated with a higher rate of adverse events (Bart, et al., 2012, PMID: [23131078](http://pubmed.ncbi.nlm.nih.gov/23131078/)).<br>
DOI: 10.60645/bdc-tp81-b8b7
title: Heart Failure Network: Diuretic Optimization Strategies Evaluation in Acute Heart Failure (HFN DOSE-BioLINCC)

description: 
<u>Objectives</u><br>The DOSE study sought to evaluate the most effective dosing (high vs. low) and administration (continuous infusion vs. intermittent boluses) combination of the diuretic Furosemide in the treatment of patients with acute decompensated heart failure.

<u>Background</u><br>Acute decompensated heart failure is the most common cause of hospital admissions among patients older than 65 years of age and is responsible for more than 1 million hospitalizations annually in the United States. Intravenous loop diuretics are an essential component of current treatment and are administered to approximately 90% of patients who are hospitalized with heart failure. Despite decades of clinical experience with these agents, prospective data to guide the use of loop diuretics are sparse, and current guidelines are based primarily on expert opinion. As a result, clinical practice varies widely with regard to both the mode of administration and the dosing.<br>

<u>Subjects</u><br>A total of 308 patients were enrolled between March 2008 and November 2009 at 26 clinical sites in the United States and Canada. <br>

<u>Design</u><br>The DOSE study was a prospective, randomized, double-blind, controlled trial with a 2-by-2 factorial design. Patients were randomly assigned to either a low-dose strategy (total intravenous furosemide dose equal to their total daily oral loop diuretic dose in furosemide equivalents) or a high-dose strategy (total daily intravenous furosemide dose 2.5 times their total daily oral loop diuretic dose in furosemide equivalents) and to administration of furosemide either by intravenous bolus every 12 hours or by continuous intravenous infusion.<br>

The study treatment, with group assignments concealed, was continued for up to 72 hours. At 48 hours, the treating physician had the option of adjusting the diuretic strategy on the basis of the clinical response. An assessment of biomarkers, including creatinine, cystatin C, and N-terminal pro-brain natriuretic peptide, was performed at a central core laboratory at baseline, 72 hours, and 60 days. Patients were followed for clinical events to day 60. The coprimary end points were patients' global assessment of symptoms, quantified as the area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and the change in the serum creatinine level from baseline to 72 hours.<br>

<u>Conclusions</u><br>Among patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose as compared with a low dose. (Felker et. al., 2011, PMID: [21366472](http://pubmed-ncbi-nlm-nih-gov.ezproxy.nihlibrary.nih.gov/21366472/))<br>
DOI: 10.60645/bdc-2628-5gfd
title: Sickle Cell Disease Natural History Data Resource (SCD NHDR)

description: 
**Background**

The NHLBI initiated the Sickle Cell Disease Natural History Data Resource (SCD NHDR) to leverage existing SCD studies to build a data resource to provide phenotypic data on contemporaneous control cohorts for gene therapy trials and other studies. The potential uses of the NHDR are broad, including providing matched controls for clinical trials, observing a cohort of untreated patients as part of a natural history study, or conducting comparative effectiveness research on a subpopulation with selected co-morbidities or drug treatment profiles. The SCD NHDR includes two multi-center SCD longitudinal cohort studies with extensive annual clinical data and patient surveys, the Sickle Cell Disease Implementation Consortium (SCDIC-I and SCDIC-II) and the Globin Research Network for Data and Discovery (GRNDaD). The SCDIC-I, initiated in 2017 and concluded in June 2022, enrolled over 2400 patients with SCD from 8 US treatment centers. The SCDIC-II reconsented 1220 of the SCDIC-I patients as well as enrolling an additional 450 new patients from the same 8 centers between September 2022 and October 2023, for a total of 1670 in SCDIC-II. Only two of the many GRNDaD centers are submitting data to the SCD NHDR for deposit into BDC (approximately 130 patients). Data submissions from the SCD NHDR to BDC will be annually starting in early 2024. 

**Description of the Study Data **

All data obtained for the SCD NHDR are considered common data elements (CDEs) important for studies of SCD. These CDEs were identified from several workgroups of SCD experts convened under the NHLBI's [Cure-SC](https://curesickle.org/cde-catalog) Initiative ([https://curesickle.org/cde-catalog](https://curesickle.org/cde-catalog)). 

The following types of data elements were abstracted from the medical record &#8211; variables that describe the SCD diagnosis, SCD co-morbidities and other clinical complications, elements from the physical examination, medications and transfusions, insurance type, laboratory measurements, healthcare utilization, history of SCD-related procedures, and measurements from cardiac procedures. 

The following types of data were self-reported on the patient survey &#8211; demographics, diagnosis information, pain experience, social and mental health information, other patient reported outcome domains (e.g., sleep, fatigue), and alcohol and smoking history. Standard PRO measures were used from ASCQ-Me, PROMIS and Neuro-QoL. 

Patient surveys were completed approximately annually. Under SCDIC-I, two medical record abstractions and labs were reported at enrollment and approximately 3 years later. Under SCDIC-II and GRNDaD, all data are collected annually. Patients may refuse to complete the survey.
DOI: 10.60645/bdc-uxy9-717e
title: Sickle Cell Disease Natural History Data Resource (SCD NHDR)

description: 
**Background**

The NHLBI initiated the Sickle Cell Disease Natural History Data Resource (SCD NHDR) to leverage existing SCD studies to build a data resource to provide phenotypic data on contemporaneous control cohorts for gene therapy trials and other studies. The potential uses of the NHDR are broad, including providing matched controls for clinical trials, observing a cohort of untreated patients as part of a natural history study, or conducting comparative effectiveness research on a subpopulation with selected co-morbidities or drug treatment profiles. The SCD NHDR includes two multi-center SCD longitudinal cohort studies with extensive annual clinical data and patient surveys, the Sickle Cell Disease Implementation Consortium (SCDIC-I and SCDIC-II) and the Globin Research Network for Data and Discovery (GRNDaD). The SCDIC-I, initiated in 2017 and concluded in June 2022, enrolled over 2400 patients with SCD from 8 US treatment centers. The SCDIC-II reconsented 1220 of the SCDIC-I patients as well as enrolling an additional 450 new patients from the same 8 centers between September 2022 and October 2023, for a total of 1670 in SCDIC-II. Only two of the many GRNDaD centers are submitting data to the SCD NHDR for deposit into BDC (approximately 130 patients). Data submissions from the SCD NHDR to BDC will be annually starting in early 2024. 

**Description of the Study Data **

All data obtained for the SCD NHDR are considered common data elements (CDEs) important for studies of SCD. These CDEs were identified from several workgroups of SCD experts convened under the NHLBI's [Cure-SC](https://curesickle.org/cde-catalog) Initiative ([https://curesickle.org/cde-catalog](https://curesickle.org/cde-catalog)). 

The following types of data elements were abstracted from the medical record &#8211; variables that describe the SCD diagnosis, SCD co-morbidities and other clinical complications, elements from the physical examination, medications and transfusions, insurance type, laboratory measurements, healthcare utilization, history of SCD-related procedures, and measurements from cardiac procedures. 

The following types of data were self-reported on the patient survey &#8211; demographics, diagnosis information, pain experience, social and mental health information, other patient reported outcome domains (e.g., sleep, fatigue), and alcohol and smoking history. Standard PRO measures were used from ASCQ-Me, PROMIS and Neuro-QoL. 

Patient surveys were completed approximately annually. Under SCDIC-I, two medical record abstractions and labs were reported at enrollment and approximately 3 years later. Under SCDIC-II and GRNDaD, all data are collected annually. Patients may refuse to complete the survey.
DOI: 10.60645/bdc-5390-th7p
title: Heart Failure Network: Functional Impact of GLP-1 for Heart Failure Treatment (HFN FIGHT-BioLINCC)

description: 
<u>Objectives </u><br>To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. 

<u>Background </u><br>Heart failure was the leading cause of hospitalization in the United States with more than 4 million admissions per year from 2003&#8211;2009. Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). As heart failure progresses, these abnormalities become more pronounced and are observed in both patients with and without type 2 diabetes. At this time of this study, there was no heart failure therapy that targeted these metabolic abnormalities; however, in earlier clinical studies, glucagon-like peptide 1 (GLP-1) agonists showed cardioprotective effects in patients with advanced heart failure, irrespective of type 2 diabetes status. Glucagon-like peptide 1 is an endogenous incretin hormone that improves insulin sensitivity with minimal risk of hypoglycemia. This study was created to determine if use of GLP-1 agonists improved clinical stability in recently hospitalized patients with acute heart failure and reduced LVEF. 

<u>Participants </u><br>There were 300 participants. 

<u>Design </u><br>Participants were identified by hospital admission records and were enrolled during either the last 24 hours of his or her hospitalization for heart failure or the 2-week interval after the hospitalization. Baseline evaluations were conducted, which included echocardiographic measures, the 6-minute walk test, the Kansas City Cardiomyopathy Questionnaire (KCCQ), and blood tests. 

After the baseline evaluation, patients were randomized in a 1:1 ratio to receive either the GLP-1 agonist liraglutide or placebo as a daily subcutaneous injection. The protocol involved titration of study drug dosage as tolerated every 14 days from 0.6 mg/d to 1.2 mg/d to 1.8 mg/d during the first 30 days of the trial (as tolerated). Follow-up testing was performed at 30-, 90-, and 180-day study visits. 

The primary end point was a global rank score in which all participants, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level from baseline to 180 days. 

<u>Conclusions </u><br>The GLP-1 agonist liraglutide did not improve post-hospitalization clinical stability in patients with advanced heart failure and reduced LVEF. There was no significant between-group difference in the global rank scores and furthermore, there were no significant differences detected in any of the secondary endpoints.
DOI: 10.5281/zenodo.18504904
title: Cell-level measurements, lineage annotations and clinical metadata for "Robust multicellular programs dissect the complex tumor microenvironment and track disease progression in colorectal cancer"

description: Cell-level measurements, lineage annotations and clinical metadata for "Robust multicellular programs dissect the complex tumor microenvironment and track disease progression in colorectal cancer"

Preprint: https://doi.org/10.48550/arXiv.2510.05083Code: https://doi.org/10.5281/zenodo.17186802

Description:



cell_table.csv: intensity measured per channel and per cell, and cell location and shape descriptors, after artefact filtering (plain text CSV). Use the column fov to map it to the metadata.

adata_consensus_cell_types.h5ad: cell-level measurements including cell type annotation (AnnData format). Use obs['fov'] to map it to the metadata.

summary_clinical_data_modified.csv: clinical annotation per sample (plain text CSV). Use the column TMA Localisation to map it to the measurements.


These files are proposed as entry points in reproducing or expanding our analyses. See the repository linked for the details of how the data is processed, and the preprint for scientific context. Multiplexed images and segmentation masks will be provided separately (BioImage Archive).
DOI: 10.60645/bdc-m2o1-5l2o
title: National Sleep Research Resource (NSRR): Hispanic Community Health Study/Study of Latinos

description: 
The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH) contributed to the first phase of the project. 

Raw polysomnography data are available from the HCHS/SOL Baseline visit and raw actigraphy data are available from the Sue&#241;o Ancillary visit. 

Primary HCHS/SOL data can be requested through [dbGaP phs000810 Hispanic Community Health Study /Study of Latinos (HCHS/SOL)](./study.cgi?study_id=phs000810).
DOI: 10.5281/zenodo.18504903
title: Cell-level measurements, lineage annotations and clinical metadata for "Robust multicellular programs dissect the complex tumor microenvironment and track disease progression in colorectal cancer"

description: Cell-level measurements, lineage annotations and clinical metadata for "Robust multicellular programs dissect the complex tumor microenvironment and track disease progression in colorectal cancer"

Preprint: https://doi.org/10.48550/arXiv.2510.05083Code: https://doi.org/10.5281/zenodo.17186802

Description:



cell_table.csv: intensity measured per channel and per cell, and cell location and shape descriptors, after artefact filtering (plain text CSV). Use the column fov to map it to the metadata.

adata_consensus_cell_types.h5ad: cell-level measurements including cell type annotation (AnnData format). Use obs['fov'] to map it to the metadata.

summary_clinical_data_modified.csv: clinical annotation per sample (plain text CSV). Use the column TMA Localisation to map it to the measurements.


These files are proposed as entry points in reproducing or expanding our analyses. See the repository linked for the details of how the data is processed, and the preprint for scientific context. Multiplexed images and segmentation masks will be provided separately (BioImage Archive).
DOI: 10.60645/bdc-d16j-463n
title: National Sleep Research Resource (NSRR): Hispanic Community Health Study/Study of Latinos

description: 
The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH) contributed to the first phase of the project. 

Raw polysomnography data are available from the HCHS/SOL Baseline visit and raw actigraphy data are available from the Sue&#241;o Ancillary visit. 

Primary HCHS/SOL data can be requested through [dbGaP phs000810 Hispanic Community Health Study /Study of Latinos (HCHS/SOL)](./study.cgi?study_id=phs000810).
DOI: 10.5281/zenodo.18482541
title: Data on renewable targets

description: Data on renewable targets

This dataset contains detailed, machine-readable data on renewable (electricity and final energy consumption) targets for the EU-27 for the years 2001-2023.

This dataset was developed by Aksornchan Chaianong, Dogukan Günkördü, and Puru Malhotra, from 2024 to January 2026. Aksornchan Chaianong led the work, with support from Ioannis Milioritsas, Silvia Weko, and Johan Lilliestam.

The data is published with CC BY-SA 4.0. Please cite it as:

Chaianong, A., Günkördü, D., Malhotra P., Milioritsas, I., Weko, S., and Lilliestam, J. (2025): Data on renewable targets (Version 2, January 2026). Sustainability Transition Policy Group, Friedrich-Alexander-Universität Erlangen-Nürnberg. DOI: 10.5281/zenodo.18482541. 

The authors would like to thank the German Federal Government, the German State Governments, and the Joint Science Conference (GWK) for their funding and support as part of the NFDI4Energy consortium. The work was funded by the German Research Foundation (DFG) – 501865131 within the German National Research Data Infrastructure (NFDI, www.nfdi.de). Aksornchan Chaianong would also like to thank the Office for Equal Opportunities for Women in Science and the Arts at the School of Business, Economics, and Law at FAU Erlangen-Nürnberg for the Individual Career Development funding.

The data are, to the best of our knowledge, correct, but we assume no responsibility for any remaining data errors or publication errors. Should you find errors or have data to fill gaps, please contact climatepolicyatlas@nfdi4energy.org.

Note: the previous version of the dataset is V1, and is no longer up to date.
DOI: 10.5281/zenodo.15476148
title: Data on renewable targets

description: Data on renewable targets

This dataset contains detailed, machine-readable data on renewable (electricity and final energy consumption) targets for the EU-27 for the years 2001-2023.

This dataset was developed by Aksornchan Chaianong, Dogukan Günkördü, and Puru Malhotra, from 2024 to January 2026. Aksornchan Chaianong led the work, with support from Ioannis Milioritsas, Silvia Weko, and Johan Lilliestam.

The data is published with CC BY-SA 4.0. Please cite it as:

Chaianong, A., Günkördü, D., Malhotra P., Milioritsas, I., Weko, S., and Lilliestam, J. (2025): Data on renewable targets (Version 2, January 2026). Sustainability Transition Policy Group, Friedrich-Alexander-Universität Erlangen-Nürnberg. DOI: 10.5281/zenodo.18482541. 

The authors would like to thank the German Federal Government, the German State Governments, and the Joint Science Conference (GWK) for their funding and support as part of the NFDI4Energy consortium. The work was funded by the German Research Foundation (DFG) – 501865131 within the German National Research Data Infrastructure (NFDI, www.nfdi.de). Aksornchan Chaianong would also like to thank the Office for Equal Opportunities for Women in Science and the Arts at the School of Business, Economics, and Law at FAU Erlangen-Nürnberg for the Individual Career Development funding.

The data are, to the best of our knowledge, correct, but we assume no responsibility for any remaining data errors or publication errors. Should you find errors or have data to fill gaps, please contact climatepolicyatlas@nfdi4energy.org.

Note: the previous version of the dataset is V1, and is no longer up to date.